Agree Realty's BioDlink Achieves Milestone in Biopharma with MEIYOUHENG Approval
- BioDlink aids Lepu Biopharma in receiving conditional approval for the world's first non-photoimmunological EGFR-targeted ADC.
- The company's success in biologics commercialization demonstrates a 100% first-pass success rate across key development stages.
- BioDlink's focus on biologics positions it well in the biopharmaceutical market, supporting advancements in targeted therapies.
BioDlink's Groundbreaking Approval Marks a New Era in Biopharma Collaboration
BioDlink (1875.HK) achieves a significant milestone by assisting its partner Lepu Biopharma (2157.HK) in receiving conditional marketing approval from China’s National Medical Products Administration (NMPA) for the innovative MEIYOUHENG (Becotatug Vedotin injection). This drug, an EGFR-targeted antibody-drug conjugate (ADC), is specially designed for treating recurrent or metastatic nasopharyngeal carcinoma (R/M NPC). This approval, granted on October 30, 2025, is particularly noteworthy as it represents the world’s first non-photoimmunological EGFR-targeted ADC. The accomplishment not only highlights BioDlink's pioneering efforts in biopharma but also sets the stage for its inaugural global commercial ADC manufacturing initiative.
The success of the MEIYOUHENG project underscores BioDlink's robust capabilities in biologics commercialization, achieving a remarkable 100% first-pass success rate across crucial development stages. These include technology transfer, Process Performance Qualification (PPQ), and Pre-Approval Inspection (PAI). Such efficiency is vital in the biopharma space, where time-to-market can significantly impact patient outcomes and market competitiveness. By managing the entire production cycle—from technology transfer to clinical sample manufacturing—BioDlink showcases its end-to-end capabilities to support complex biologics from the initial research phase to the final launch in the marketplace.
Moreover, the achievement reflects BioDlink's commitment to establishing an integrated quality management system in collaboration with Lepu Biopharma and regulatory authorities. This system ensures compliance with global Good Manufacturing Practice (GMP) standards, receiving certifications from key markets such as China, the United States, and the European Union, alongside Foreign Manufacturer Approval from Japan's PMDA. This collaborative model exemplifies how effective partnerships can streamline multi-party efforts in the biopharma industry, thus enhancing the ability to meet stringent regulatory timelines and prepare for commercial readiness in global markets.
In addition to its recent approval, BioDlink's strategic focus on biologics production positions it favorably in the rapidly evolving biopharmaceutical landscape. With the increasing demand for targeted therapies, BioDlink's advancements in ADC technology could play a pivotal role in expanding treatment options for patients worldwide.
Related Cashu News

Lamar Advertising Co Moves to Value Indices Amid Shift in Investment Strategies
Lamar Advertising Co (Ticker: LAMR) has recently undergone a significant change in its market classification by being added to several Russell value and defensive indices. This inclusion reflects a sh…

Alexandria Real Estate Equities Advances Corporate Responsibility and Strengthens Its Position in Life Sciences
Alexandria Real Estate Equities (ARE) has made significant strides in enhancing its corporate responsibility efforts, as detailed in its recently published 2025 Corporate Responsibility Report. The re…

Healthpeak OP LLC Achieves Key Index Inclusion, Boosting Investor Interest and Trading Activity
Healthpeak OP LLC (Ticker: DOC) leverages significant market developments to reinforce its position in the real estate investment trust sector through strategic index inclusion, which may reshape inve…

Public Storage Boosts Financial Flexibility with New Credit Facility and Commercial Paper Program
Public Storage (Ticker: PSA) enhances its financial flexibility with a new unsecured credit facility and commercial paper program. Strategic Financial Innovations The company announces the closure of…

